Phosphatidylinositol-3 kinases (PI3Ks) are a well-characterized family of lipid kinases that were originally identified by their ability to phosphorylate the 3-hydroxy group of inositol phospholipids. In normal cells, this reaction is tightly regulated and leads to the activation of several cellular processes, including metabolism, proliferation, vesicle trafficking, and survival[@b1],[@b2]. PI3Ks are divided into three different classes (I-III) based on structural homology and substrate[@b3],[@b4]. The PI3K type that is dysregulated in cancer is the Class I heterodimer, which is composed of regulatory and catalytic subunits. This class is divided into Subclass IA and Subclass IB. Subclass IA members are activated by ligand binding of receptor tyrosine kinases (RTK), whereas Subclass IB members are activated by G protein-coupled receptors. A single activated receptor may then activate multiple downstream molecules, resulting in the signal amplification of a zymogen cascade. Specifically, activated PI3Ks catalyze the phosphorylation of phosphatidylinositol-4,5 bisphosphate (PIP~2~) to produce the second messenger phosphatidylinositol-3,4,5 trisphosphate (PIP~3~). The generation of PIP~3~ activates downstream signaling effector proteins, including the serine/threonine kinase AKT. The activation of AKT molecules plays a key regulatory role by targeting multiple proteins, including Bad, FOXO, Cyclin D1, GSK3β, MDM2, P27, and the mammalian target of rapamycin (mTOR), resulting in cellular transformation, survival, and proliferation ([Figure 1](#cjc-31-07-327-g001){ref-type="fig"})[@b5],[@b6]. The Subclass IA PI3K consists of a p85 regulatory subunit and a p110 catalytic subunit. Three genes, *PIK3R1*, *PIK3R2*, and *PIK3R3*, encode three isoforms of the p85 regulatory subunit. Additionally, the *PIK3R1* gene gives rise to two shorter isoforms through alternative splicing. The five p85 isoforms have a common core structure consisting of a p110-binding domain surrounded by two Src-homology-2 domains (SH2) ([Figure 2](#cjc-31-07-327-g002){ref-type="fig"}). The three isoforms of the p110 catalytic subunit are encoded by three genes: *PIK3CA*, *PIK3CB*, and *PIK3CD*. All three isoforms possess an N-terminal p85-binding domain (also referred to an adaptor-binding domain), a Ras-binding domain, a C2 domain (membrane-binding domain), a helical domain (HD) of unknown function, and a C-terminal catalytic kinase domain (KD) ([Figure 2](#cjc-31-07-327-g002){ref-type="fig"}).

![Downstream signaling of phosphatidylinositol-3 kinase (PI3K) in cancer.\
After activation and phosphorylation of growth factor receptors by a ligand, PI3K is recruited to the membrane through the p85 adaptor subunit, resulting in the activation of the p110 catalytic subunit and production of phosphatidylinositol-3,4,5 trisphosphate (PIP~3~). This second messenger forms a docking site for cytoplasmic proteins that carry pleckstrin homology (PH) domains to the membrane, including the serine threonine kinase AKT. Once activated, AKT mediates the activity of several target proteins, which results in cell survival, proliferation, and protein synthesis. In this schematic representation, lines indicate either phosphorylation leading to activation (arrow) or inhibition (blunt end) of downstream targets. The star represents gain-of-function mutations in the p110 subunit.](cjc-31-07-327-g001){#cjc-31-07-327-g001}

![PI3K proteins and functional domains.\
The Subclass IA PI3Ks are heterodimers that consist of a p85 regulatory subunit and a p110 catalytic subunit. Key functional domains are identified. The three most common mutations in the *PIK3CA* gene are depicted with stars.](cjc-31-07-327-g002){#cjc-31-07-327-g002}

In breast cancer, somatic mutations of *PIK3CA* on chromosome 3q26 are commonly found and are reported in the literature in 18% to 40% of cases[@b7]--[@b11]. The publically available COSMIC database includes 5838 breast tumor samples, wherein 1493 tumors harbor mutations in *PIK3CA*, giving a mutation rate of 26%[@b12]. Additionally, mutations are observed in more than half of breast cancer cell lines[@b13]. This frequency suggests an important role of this gene in tumorigenesis. Furthermore, *PIK3CA* mutations induce tumor formation in transgenic mice[@b14],[@b15]. The majority of mutations occur at three hotspots: E542K, E545K, and H1047R. The first two hotspots are in the HD (exon 9), whereas the last hotspot is in the KD (exon 20) ([Figure 2](#cjc-31-07-327-g002){ref-type="fig"}). These activating *PIK3CA* mutations enhance the lipid kinase activity to a level higher than that of wild-type *PIK3CA*, leading to increased phosphorylation and activity of downstream targets[@b11]. Different mechanisms lead to the gain-of-function mutations in the HD and the KD. Recent structural analyses have shown that mutations in the HD abrogate the inhibitory interaction of the SH2 domains of p85, whereas a mutation in the KD alters the tertiary structure of the catalytic subunit such that it increases the accessibility for substrates[@b2]. Mutations in the *PIK3CA* gene are not the only deregulations of the PI3K pathway described. Gene amplification of *PIK3CA*, loss of *PTEN*, and mutations of *AKT1* have also been reported.

Considering the key regulatory functions of the PI3K pathway and its common deregulation in breast cancer, we could predict that activating mutations of *PIK3CA* relates with a more aggressive tumor, resulting in poor patient prognosis and shorter survival. To test this hypothesis, we performed a systematic review of breast cancer clinical studies.

*PIK3CA* Mutations and Breast Cancer Patient Survival: A Blurred Picture {#s2}
========================================================================

To address the clinical impact of *PIK3CA* mutations on breast cancer, we performed a search on PubMed using the following keywords: "breast", "cancer", "pik3ca", and "mutation" (December 1^st^, 2011). We identified 12 studies[@b16]--[@b27] from the 119 abstracts evaluated. Clinical characteristics of the studies are summarized in [Table 1](#cjc-31-07-327-t01){ref-type="table"}. The 12 studies reported the outcomes of 2587 breast cancer patients. The discrepancies in observed clinical outcomes are likely due to variations in patient population and tumor characteristics. In fact, the effects of *PIK3CA* mutations are likely dependent on the subtype of breast cancer and the location where the mutation in *PIK3CA* occurs. Indeed, estrogen receptor (ER)-positive and HER2-positive breast tumors are two molecularly distinct diseases that differ in both biological and clinical behaviors[@b28]. Moreover, previous studies suggest that mutations in the HD and the KD have different biological and clinical consequences.

###### Characteristics of the analyzed studies

  Study                           Total cases   Median follow-up (years)   Node positive (%)   HR positive (%)   *PIK3CA* mutation (%)  Association between *PIK3CA* mutation and prognosis (%)
  ------------------------------ ------------- -------------------------- ------------------- ----------------- ----------------------- ---------------------------------------------------------
  Kalinsky *et al.*[@b16]             590                 12.8                    42                 69                   33            Better OS (*P* = 0.03)^a^
  Maruyama *et al.*[@b17]             188                 5.3                     35                 66                   28            Better RFS (*P* = 0.02)^a^
  Barbareshi *et al.*[@b18]           163               No data                   52                 84                   53            Better OS (*P* = 0.001 )^a^
  Loi *et al.*[@b19]                  173                 9.6                     50                 100                  26            NS^b^
  Michelucci *et al.*[@b20]           176                 6.8                     51                 76                   38            NS^b^
  Boyault *et al.*[@b21]              120                  2                      78                 37                   21            NS^b^
  Perez-Tenorio *et al.*[@b22]        270                  11                     88                 70                   24            Better local RFS (*P* = 0.02)^a^
  Saal *et al.*[@b23]                 292                 4.4                     56                 55                   26            NS
  Stemke-Hale *et al.*[@b24]          157                 7.5                     35                 100                  35            NS
  Lai *et al.*[@b25]                  152                 6.6                     53                 80                   26            NS
  Li *et al.*[@b26]                   250                 4.2                     47                 69                   35            Worse OS (*P* = 0.004)
  Lerma *et al.*[@b27]                56                  6.3                     89                  0                   13            Worse OS (*P* = 0.015)

HR, hormone receptor; OS, overall survival; RFS, recurrence-free survival; NS, not significant. The association between *PIK3CA* mutations and clinicopathologic parameters is shown in the 12 studies analyzed. Association of mutation status and PFS or OS was assessed by the Kaplan-Meier method and Cox proportional hazards models with 2-sided *P* values. ^a^Multivariate analysis confirmed that the prognostic factor is independent to other conventional prognostic factors. ^b^Trend in favor of a longer OS.

In the 12 studies analyzed, 4 studies reporting outcomes of 1211 women found that *PIK3CA* mutations was associated with either a longer disease-free survival (DFS) or overall survival (OS)[@b16]--[@b18],[@b22] ([Table 1](#cjc-31-07-327-t01){ref-type="table"}). In these 4 studies, multivariate analyses confirmed that *PIK3CA* mutations were associated with a favorable prognosis regardless of other conventional prognostic factors. In the largest study, Kalinski *et al.*[@b16] analyzed samples from 590 patients with primary invasive ductal or lobular breast carcinomas, with a long-term patient follow-up of 12.8 years, using a Sequenom MassArray system. Patients with *PIK3CA* mutations had superior DFS, OS, and breast cancer-specific survival compared with those without *PIK3CA* mutations. Interestingly, analysis of *PIK3CA* mutation sites revealed that HD hotspot mutations were not associated with an improvement in OS (10-year OS rate was 62% for patients with wild-type *PIK3CA* vs. 59% for those with HD mutations, *P* = 0.54). In contrast, KD mutations was associated with superior OS when compared with wild-type *PIK3CA* (10-year OS rate was 62% for patients with wild-type *PIK3CA* vs. 76% for those with KD mutations, *P* = 0.005). A similar finding was also reported by Barbareschi *et al.*[@b18], in which patients with KD mutations showed a significantly better OS. Data from this study also demonstrated that patients with HD mutations had a worse prognosis.

Six studies did not find a significant relationship between somatic *PIK3CA* mutations and either DFS or OS[@b19]--[@b21],[@b23]--[@b25]. Nevertheless, 3 of these studies reported a favorable trend that related *PIK3CA* mutations with improved clinical outcomes. However, these differences were not significant, possibly due to the small sample size and the subsequent lack of power of these studies[@b19],[@b20],[@b24].

Against evidences presented by the above-mentioned studies, one study found that, although the OS was not significantly different in patients with all *PIK3CA* mutations, specific mutations in the KD were independently associated with a shorter OS[@b25]. Two additional studies that included 306 patients found that *PIK3CA* mutations were associated with a poor OS[@b26],[@b27]. Nevertheless, these two studies have several limitations. In the first study, by Li *et al.*[@b26], the mutation status failed to reach significance as an independent prognostic factor of OS. The second study, by Lerma *et al.*[@b27] addressed only the role of *PIK3CA* mutations in HER-2- positive breast cancer while excluding patients with hormone receptor-positive tumors.

To analyze the association between *PIK3CA* mutations and ER status, relevant studies containing data on both of these factors were combined and a strong association between *PIK3CA* mutations and ER positivity was found (*P* \< 0.001) ([Table 2](#cjc-31-07-327-t02){ref-type="table"}). Furthermore, wild-type *PIK3CA* was associated with higher tumor stage (*P* \< 0.03) ([Table 3](#cjc-31-07-327-t03){ref-type="table"}). In both cases, we excluded studies that lacked necessary information.

###### *PIK3CA* mutations and estrogen receptor (ER) status in breast cancer patients

  Study                           Estrogen receptor-positive status \[% (*n*)\]  
  ------------------------------ ----------------------------------------------- -------------------
  Kalinsky *et al.*[@b16]                         57% (225/398)                     73% (141/192)
  Maruyama *et al.*[@b17]                         61% (82/134)                       78% (42/54)
  Barbareschi *et al.*[@b18]                      83% (99/118)                       84% (38/45)
  Michelucci *et al.*[@b20]                        70% (58/82)                       85% (40/47)
  Perez-Tenorio *et al.*[@b22]                    67% (136/202)                      80% (52/65)
  Saal *et al.*[@b23]                             52% (106/204)                      78% (56/72)
  Li *et al.*[@b26]                               61% (99/162)                       78% (69/88)
  **Total**                                    **62% (743/1208)**                 **78% (415/535)**

All data are expressed as "positive rate (positive cases / total cases)." Only studies containing data on both *PIK3CA* mutations and ER status were selected. The association between *PIK3CA* mutations and ER status was assessed by the χ^2^ test with 2-sided *P* values. *PIK3CA* mutations are associated with ER positivity (*P* \< 0.001).

###### *PIK3CA* mutations and tumor stage in breast cancer patients

  Study                         Stage 3 or 4 tumors \[% (*n*)\]  
  ---------------------------- --------------------------------- -----------------
  Kalinsky *et al.*[@b16]                 6% (24/398)               4% (8/192)
  Maruyama *et al.*[@b17]                17% (19/112)                6% (3/49)
  Barbareschi *et al.*[@b18]             14% (17/118)               11% (5/45)
  Saal *et al.*[@b23]                     8% (18/215)                5% (4/77)
  Stemke-Hale *et al.*[@b24]             18% (18/101)               13% (7/56)
  **Total**                            **10% (96/944)**           **6% (27/419)**

All data are expressed as "positive rate (positive cases / total cases)." Only studies containing data on both *PIK3CA* mutations and ER status were selected. The association between *PIK3CA* mutations and tumor stages was assessed by the χ^2^ test with 2-sided *P* values. *PIK3CA* mutations are associated with few stage 3 or 4 tumors (*P* = 0.03)

We propose that the clinical benefit observed in the presence of *PIK3CA* mutations may pertain mainly to ER-positive breast tumors and mutations in the KD. The unexpected and counterintuitive observation that *PIK3CA* mutations appear to be associated with a better clinical outcome in some patients remains unsolved. Below, we propose three hypotheses to explain this paradoxical association of oncogene activation with better patient outcomes.

*PIK3CA* Mutations May Suppress Metastasis and Induce Senescence {#s3}
================================================================

As metastatic disease is the leading cause of recurrence and death in breast cancer patients, we hypothesize that the PI3K pathway activation through *PIK3CA* gain-of-function mutations, in particular in the KD domain, may suppress metastasis, which could translate into observed clinical benefits. Indeed, our analysis found that *PIK3CA* mutations were associated with lower tumor stages ([Table 3](#cjc-31-07-327-t03){ref-type="table"}). Supporting this hypothesis, Pang *et al.*[@b29] have recently shown that expression of KD mutations in MDA-MB-231 cells rendered the cells less chemotactic and led to a decrease in blood intravasation and lung extravasation *in vivo*, compared with mutations in the HD. Additionally, Yoeli-Lerner *et al.*[@b30] have shown that overexpression of *AKT1*, the major downstream target of PI3K, in breast cancer cell lines resulted in a decrease in migration and invasion. In this hypothesis, *PIK3CA* mutations may interfere with metastatic progression of breast cancer cells, while simultaneously accelerating the process of primary tumor formation. Recently, Jensen *et al.*[@b31] assessed the *PIK3CA* mutation status in both primary breast tumors and corresponding metastases and showed a high discrepancy between primary tumors and metastases with either a gain or a loss of *PIK3CA* mutation in metastases. Furthermore, in this study, *PIK3CA* mutations were associated with a longer time to recurrence. Together, these data suggest that *PIK3CA* mutations did not confer significant advantages for metastasis and may, actually, decrease the metastasis formation. To definitively address this question, it would be useful to study spontaneous metastases in genetically engineered mice (GEM) carrying *PIK3CA* mutations in combination with other oncogenic events.

An alternative hypothesis is that *PIK3CA* mutations may induce senescence, resulting in a less aggressive phenotype compared with activation of other pathways. There is substantial evidence demonstrating that activated oncogenes can induce senescence *in vitro*, and this phenomenon is a potent antitumor barrier *in vivo*[@b32]--[@b34] In this hypothesis, *PIK3CA* mutations may be important in the initiation of cell transformation but may result in senescence that has to be overcome in the tumor cell via additional genetic or epigenetic alterations.

*PIK3CA* Mutations May Increase the Chance of Early Detection of Tumors {#s4}
=======================================================================

Early detection is believed to decrease patient mortality by allowing therapeutic intervention prior to tumor metastases. In breast cancer, a study indicated that mammography led to a 15% reduction in mortality, in particular in high risk patients[@b35]. In the current analysis, we found that *PIK3CA* mutations associated with lower tumor stages, which could be explained by an early diagnosis of these tumors. As a result, we speculate that *PIK3CA* mutations may increase the probability of early detection by generating a tumor that is noticed earlier by the patient or her physician. This could be due to pain, location in the breast, or more firm nodularity. It is already well described that *PIK3CA* mutations can stimulate reorganization of the actin cytoskeleton in cells. For example, in the MCF-7 cell line, which carries a *PIK3CA* mutation, the major morphologic response to estrogen is the development of solid, large, multicellular nodules in postconfluent cultures[@b36],[@b37]. In this case, the typical epithelial organization is lost to allow for multilayering and nodulation, which lead to changes in the architecture of the cytoskeleton system. This reorganization may change the density of the tumor, increasing the detectability of breast tumors by self-examination, physician examination, and x-ray mammography.

*PIK3CA* Mutations May Be a Favorable Predictive Factor for Response to Hormonal Therapy {#s5}
========================================================================================

The last potential explanation for why *PIK3CA* mutations are associated with an increase in survival rate of some patients is that, although these mutations may enhance tumorigenicity, the same mutations may improve the response to treatments. In this hypothesis, *PIK3CA* mutations may increase hormonal therapy (tamoxifen) sensitivity and would not be a prognostic factor but rather a predictive factor for response. Our study found that *PIK3CA* mutations were significantly higher in ER-positive tumors than in ER-negative tumors ([Table 2](#cjc-31-07-327-t02){ref-type="table"}). We speculate that this positive association between *PIK3CA* mutations and ER-positive tumors is due to cross-talk between the PI3K and ER pathways. Indeed, it has been shown that AKT phosphorylates the Ser167 residue of ER and increases its transcriptional activity, resulting in the preferential growth of ER-positive cells in the presence of *PIK3CA* mutations. Additionally, it is possible that negative feedback secondary to PI3K activation yields insensitivity to growth factor receptor stimulation, delaying the development of hormonal therapy resistance. Given that almost all ER-positive breast cancer patients are treated with tamoxifen or aromatase inhibitors, the generally favorable prognosis observed in *PIK3CA*-mutated tumors may simply be the consequence of a specific sensitivity of these tumors to hormonal therapy.

*PIK3CA* Mutations and the Clinical Development of PI3K Inhibitors {#s6}
==================================================================

Several drugs targeting PI3K are currently being evaluated in clinical trials, particularly in breast cancer ([Table 4](#cjc-31-07-327-t04){ref-type="table"})[@b38],[@b39]. These molecules include pan-PI3K inhibitors, PI3Kα inhibitors, and dual PI3K/mTOR inhibitors. The association of *PIK3CA* mutations and good clinical outcomes does not mean that patients with *PIK3CA* mutations will not benefit from PI3K inhibitors. Some results from early clinical trials using PI3K inhibitors (BKM120, BEZ235, and XL147) are already available[@b40]--[@b43]. Although the data show a modest activity of these drugs as a single agent with a response rate of approximately 10%, patients with *PIK3CA* mutations seem to have a higher response rate than patients with wild-type *PIK3CA.* Nevertheless, these phase I trials included few breast cancer patients and the results need to be confirmed in randomized clinical trials to draw definitive conclusions. Additionally, as is the case with other targeted therapies, a combined approach is more likely to produce a better clinical response than a single-agent strategy.

###### Agents targeting PI3K currently being tested in breast cancer clinical trials

  Drug                   Target            Clinical trial      Company
  ------------ -------------------------- ---------------- ---------------
  BEZ235        PI3K/mT0R dual inhibitor      Phase I         Novartis
  BGT226        PI3K/mT0R dual inhibitor      Phase II        Novartis
  BKM120           pan-PI3K inhibitor         Phase II        Novartis
  BYL719            PI3Kα inhibitor           Phase I         Novartis
  GDC0941           PI3Kα inhibitor           Phase II        Genentech
  GDC0032           PI3Kα inhibitor           Phase I         Genentech
  GSK1059615    PI3K/mT0R dual inhibitor      Phase I            GSK
  INK1117           PI3Kα inhibitor           Phase I        Intellikine
  PF04691502    PI3K/mT0R dual inhibitor      Phase II         Pfizer
  PKI587        PI3K/mT0R dual inhibitor      Phase I          Pfizer
  PX866            pan-PI3K inhibitor         Phase I        Oncothyreon
  XL147             PI3Kα inhibitor           Phase II        Exelixis
  XL765         PI3K/mT0R dual inhibitor      Phase II        Exelixis
  ZSTK474            PI3K inhibitor           Phase I       Zenyaku Kogyo

Information from [www.ClinicalTrials.gov](www.ClinicalTrials.gov).

Conclusions {#s7}
===========

The role of the PI3K pathway in oncogenesis has been extensively studied in breast cancer. Genetic aberrations of this pathway, such as *PIK3CA* mutations, loss of PTEN, and AKT activation, make this pathway a commonly activated one in breast cancer. As a result, this pathway has become an attractive target for drug development. To date, more than ten molecules targeting PI3K are being tested in clinical trials. The present analysis of several retrospective studies revealed a counterintuitive finding that gain-of-function mutations in *PIK3CA* are associated with superior clinical outcome in breast cancer patients, in particular for women with ER-positive tumors and mutations in the KD. As is frequently the case in translational research, these clinical data encourage us to look more closely at the biology of this pathway to develop a true understanding of the mechanisms underlying this paradoxical observation. This knowledge will have important implications for developing rational therapeutics for breast cancers harboring *PIK3CA* mutations.
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